Evidence map›Paper›PMID 37687089›Full record

ArticleMolecules (Basel, Switzerland)2023

Lysozyme Modification Using Proteolytic Enzymes.

Łukasz Tomczyk, Grzegorz Leśnierowski, Renata Cegielska-Radziejewska

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Łukasz TomczykDepartment of Food Quality and Safety Management, Poznan University of Life Sciences, 60-624 Poznan, Poland.ORCID 0000-0002-4644-0111
Grzegorz LeśnierowskiDepartment of Food Quality and Safety Management, Poznan University of Life Sciences, 60-624 Poznan, Poland.ORCID 0000-0002-9674-9803
Renata Cegielska-RadziejewskaDepartment of Food Quality and Safety Management, Poznan University of Life Sciences, 60-624 Poznan, Poland.ORCID 0000-0002-3554-5276
University of Life Sciences in Poznań · PL

Funding

Poznań University of Life Sciences 12/2022/Pierwszy grant
6 · The paper itself

Abstract

The lysozyme in the chicken egg white consists of various bioactive amino acids. However, these compounds are inactive when they are in the sequence of parent proteins. They become active only when isolated from these proteins. The aim of this study was to modify lysozyme with proteolytic enzymes under specific conditions of the reaction environment so as to obtain active biopeptides. The physicochemical properties of the resulting preparations were also assessed. Our study showed that the modification of lysozyme with hydrolytic enzymes (pepsin and trypsin) under strictly specified conditions resulted in obtaining biopeptide preparations with new and valuable properties, as compared with native lysozyme. After the enzymatic modification of lysozyme, two structural fractions were distinguished in the composition of the resulting preparations-the monomeric fraction and the peptide fraction. The modified lysozyme exhibited high surface hydrophobicity and high total antibacterial activity despite the decrease in the hydrolytic activity. Modification of lysozyme with hydrolytic enzymes, especially pepsin, resulted in preparations with very good antioxidative properties.

Indexed as

Dermatologic AgentsMuramidaseHydrolysisPepsin APeptide HydrolasesDermatologic AgentsMuramidasePepsin APeptide Hydrolasesantimicrobial activityantioxidant activitybioactive peptidesenzymatic hydrolysishydrolytic activityhydrophobic activitylysozyme

Identifiers

PMID37687089
PMCPMC10488540
OpenAlexW4386223657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.